Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice
Luis R. Rodriguez, Soon Yew Tang, Willy Roque Barboza, Aditi Murthy, Yaniv Tomer, Tian-Quan Cai, Swati Iyer, Katrina Chavez, Ujjalkumar Subhash Das, Soumita Ghosh, Charlotte H. Cooper, Thalia T. Dimopoulos, Apoorva Babu, Caitlin Connelly, Garret A. FitzGerald, Michael F. Beers
Luis R. Rodriguez, Soon Yew Tang, Willy Roque Barboza, Aditi Murthy, Yaniv Tomer, Tian-Quan Cai, Swati Iyer, Katrina Chavez, Ujjalkumar Subhash Das, Soumita Ghosh, Charlotte H. Cooper, Thalia T. Dimopoulos, Apoorva Babu, Caitlin Connelly, Garret A. FitzGerald, Michael F. Beers
View: Text | PDF
Research Article Pulmonology

PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic parenchymal lung disease characterized by repetitive alveolar cell injury, myofibroblast proliferation, and excessive extracellular matrix deposition for which unmet need persists for effective therapeutics. The bioactive eicosanoid, prostaglandin F2α, and its cognate receptor FPr (Ptgfr) are implicated as a TGF-β1–independent signaling hub for IPF. To assess this, we leveraged our published murine PF model (IER-SftpcI73T) expressing a disease-associated missense mutation in the surfactant protein C (Sftpc) gene. Tamoxifen-treated IER-SftpcI73T mice developed an early multiphasic alveolitis and transition to spontaneous fibrotic remodeling by 28 days. IER-SftpcI73T mice crossed to a Ptgfr-null (FPr–/–) line showed attenuated weight loss and gene dosage–dependent rescue of mortality compared with FPr+/+ cohorts. IER-SftpcI73T/FPr–/– mice also showed reductions in multiple fibrotic endpoints for which administration of nintedanib was not additive. Single-cell RNA-Seq, pseudotime analysis, and in vitro assays demonstrated Ptgfr expression predominantly within adventitial fibroblasts, which were reprogrammed to an “inflammatory/transitional” cell state in a PGF2α /FPr-dependent manner. Collectively, the findings provide evidence for a role for PGF2α signaling in IPF, mechanistically identify a susceptible fibroblast subpopulation, and establish a benchmark effect size for disruption of this pathway in mitigating fibrotic lung remodeling.

Authors

Luis R. Rodriguez, Soon Yew Tang, Willy Roque Barboza, Aditi Murthy, Yaniv Tomer, Tian-Quan Cai, Swati Iyer, Katrina Chavez, Ujjalkumar Subhash Das, Soumita Ghosh, Charlotte H. Cooper, Thalia T. Dimopoulos, Apoorva Babu, Caitlin Connelly, Garret A. FitzGerald, Michael F. Beers

×

Figure 4

Ptgfr deficiency has no effect on early lung injury and inflammation in IER-SftpcI73T.

Options: View larger image (or click on image) Download as PowerPoint

Ptgfr deficiency has no effect on early lung injury and inflammation in...
(A and B) Quantification of total protein and total cell counts in BALF did not result in a significant difference between IER-SftpcI73T/Ptgfr+/+ (n = 17) and IER-SftpcI73T/Ptgfr–/– (n = 16) mice 14 days after TAM induction. Ordinary 1-way ANOVA testing was performed. ***P < 0.005, ****P < 0.0005. (C) BALF cell differential determined by quantification of modified Giemsa-stained cytospins yielded no significant difference between IER-SftpcI73T/Ptgfr+/+ (n = 9) and IER-SftpcI73T/Ptgfr–/– (n = 7) mice 14 days after TAM induction. (D) Representative Giemsa-stained images from IER-SftpcI73T/Ptgfr+/+ and IER-SftpcI73T/Ptgfr–/– mice 14 days after TAM induction. Total original magnification, ×100. (E) Flow cytometry quantification of whole-lung single-cell suspensions confirms that there is no differential immune cell infiltration between IER-SftpcI73T/Ptgfr+/+ (n = 5) and IER-SftpcI73T/Ptgfr–/–(n = 5) mice 14 days after TAM induction. Ordinary 1-way ANOVA testing was performed for this analysis.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts